RedHill Biopharma Has Received A Notice Of Allowance For Its U.S. Patent Application 17/900,235 Titled "BIOMARKERS OF CORONAVIRUS PNEUMONIA (FOR TREATING CORONAVIRUS INFECTION OR PREVENTING DISEASES CAUSED BY CORONAVIRUS INFECTION)"
RedHill Biopharma Has Received A Notice Of Allowance For Its U.S. Patent Application 17/900,235 Titled "BIOMARKERS OF CORONAVIRUS PNEUMONIA (FOR TREATING CORONAVIRUS INFECTION OR PREVENTING DISEASES CAUSED BY CORONAVIRUS INFECTION)"
redhill biopharma已獲得17/900,235號美國專利申請的通知書，題爲“冠狀病毒肺炎生物標誌物（用於治療冠狀病毒感染或預防由冠狀病毒感染引起的疾病）”。
RedHill Biopharma Has Received A Notice Of Allowance For Its U.S. Patent Application 17/900,235 Titled "BIOMARKERS OF CORONAVIRUS PNEUMONIA (FOR TREATING CORONAVIRUS INFECTION OR PREVENTING DISEASES CAUSED BY CORONAVIRUS INFECTION)"
redhill biopharma已獲得17/900,235號美國專利申請的通知書，題爲“冠狀病毒肺炎生物標誌物（用於治療冠狀病毒感染或預防由冠狀病毒感染引起的疾病）”。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。